Galderma Group AG
GALD.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$38.46B
Close$
$177.64
5.6% upside
Current Fair Value
5.6% upsideUndervalued by 5.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $38.46 Billion |
|---|---|
| Enterprise Value | $41.13 Billion |
| Dividend Yield | $0.35 (0.21%) |
| Earnings per Share | $2.72 |
| Beta | -0.1 |
| Outstanding Shares | 189,743,000 |
Return
| Return on Equity | 15.09% |
|---|---|
| Return on Assets | 9.16% |
| Return on Invested Capital | 15.62% |
Valuation & Multiples
| P/E Ratio | 48.56 |
|---|---|
| PEG | 45.18 |
| Price to Sales | 3.06 |
| Price to Book Ratio | 3.91 |
| Enterprise Value to Revenue | 3.88 |
| Enterprise Value to EBIT | 23.05 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$2.25
Average shareholder expectationRevenue Estimate
$2.46 B
Average shareholder expectationNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
$2.10
Average shareholder expectationRevenue Estimate
$2.73 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galderma Group AG
7,676 employees
CEO: Flemming Ørnskov Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic de...